Avanos Medical, Inc. (NYSE: AVNS) reported Q2 EPS of $0.34, $0.05 better than the analyst estimate of $0.29. Revenue for the quarter came in at $171.7 million versus the consensus estimate of $170.67 million.

GUIDANCE:

Avanos Medical, Inc. sees FY2024 EPS of $1.30-$1.45, versus the consensus of $1.38. Avanos Medical, Inc. sees FY2024 revenue of $685-705 million, versus the consensus of $695.4 million.

For earnings history and earnings-related data on Avanos Medical, Inc. (AVNS) click here.